Abstract
Our integrative analysis has successfully linked the antitumor effects of SGI-110 to detailed epigenetic alterations in HCC cells, identified potential therapeutic targets, and provided a rationale for combination treatments of SGI-110 with immune checkpoint therapies.
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have